Contract Notice Detail
Summary Information
Summary Information
Base Total Price:
17,100.000000 Euro
Request Reference:
4/03766/24
Request Name:
Aquisição de LENVATINIB [10 MG; CÁP/ COMP] ao abrigo do acordo quadro 2023/491
Phase:
Tendering Phase
State:
Awarded
Description:
Aquisição de LENVATINIB [10 MG; CÁP/ COMP] ao abrigo do acordo quadro 2023/491
Procedure Type:
VortalGOV - Acquisition under a Framework Agreement (via Direct Award)
Lot Name
Lot Base Price
Expected Duration
A729 - ABACAVIR + LAMIVUDINA (Comp.Revest.)[600 + 300 MG; COMP]
-
5
(
Months
)
Object of the Contract
Object of the Contract
Type of Contract:
Supplies Acquisition
Main Object CPV Main Category:
Sete Fontes - S. Vitor 4710-243 Braga PORTUGAL
CPV Main Vocabulary
33600000-6 - Pharmaceutical products
CPV Supplementary Vocabulary
Additional Classifications List
Scheduling
Scheduling
Request online publishing date:
8/5/2024 2:57 PM
(UTC +1 hour)
National official publishing date and time (DR):
1/19/2022 2:54 PM
(UTC 0 hours)
Due datetime for receiving replies:
8/7/2024 9:00 AM
(UTC +1 hour)
Financial Settings
Financial Settings
Define Warranties?
No
Contract Documents
Contract Documents
Document Name
Description
Doc Classification
Convite - AAQ 4_03766_24 - 2022.40.pdf
Convite - AAQ 4_03766_24 - 2022.40.pdf
Download
Object of contract
This contract is subject to renewal?
No
The procurement is related to a project and/or programme financed by European Union funds?
No
Legal, economic, financial and technical information
The contract is reserved to sheltered workshops and economic operators aiming at the social and professional integration of disabled or disadvantaged persons?
No
Questionnaire
Questionnaire
1
Lot Title
A729 - ABACAVIR + LAMIVUDINA (Comp.Revest.)[600 + 300 MG; COMP]
Base Price
17 100,000000
1.1
Bill of Quantities
*
This price list has extra requirements. Make sure everything is completed, under each article line.
Item Code
Description
Quantity
Unit
A729
ABACAVIR + LAMIVUDINA (Comp.Revest.)[600 + 300 MG; COMP]
4 500,000000
NXTWY.UMT.19645
Buyer Comment:
502248793 | Mylan, Lda. | CPA:2022040/120/0074 | NºAIM:5730262; 508107997 | Generis Farmacêutica, S.A. | CPA:2022040/263/0029 | NºAIM:5690615;
TOTAL
(The amounts shown do not include VAT)
Evaluation
Evaluation
Vision
Avaliação
Definir modelo de avaliação
Sim
Não
Modalidade de avaliação
Selecione…
Monofator
Método de Avaliação
Selecione…
Manual
Divulgar critérios de avaliação
Sim
Não
Critérios da Avaliação
1 - A729 - ABACAVIR + LAMIVUDINA (Comp.Revest.)[600 + 300 MG; COMP]
Critérios da Avaliação
Descrição
Tipo de Fator
Peso (%)
1.
Preço
Preço
100%
Normas de desempate
Definir normas de desempate?
Sim
Não
Normas de desempate
Nível
Tipo de Norma
Descrição
Critério
1
Sorteio
presencial
-
Public Messages
Public Messages
Type
Reference
Subject
Date
No items found...